Investor Alert

New York Markets Close in:

Market Pulse Archives

March 30, 2020, 8:01 a.m. EDT

First patient treated in Regeneron, Sanofi trial for COVID-19 treatment

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regeneron Pharmaceuticals Inc. (REGN)
  • X
    Sanofi ADR (SNY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN -0.53% and Sanofi SA /zigman2/quotes/201967021/composite SNY -2.67% said Monday that the first patient in a global clinical trial testing Kevzara as a therapy for patients hospitalized with severe cases of COVID-19 has been treated. The patient is not located in the U.S., though the Phase 2/3 trial is being conducted in seven countries, including the U.S. A second trial is based in the U.S. The companies developed and marketed Kevzara as a treatment for rheumatoid arthritis. "These trials will provide important data to determine whether Kevzara ameliorates the life-threatening complications of COVID-19 infections by counteracting the overactive inflammatory immune responses in the lungs when damaged by the virus," Dr. John Reed, Sanofi's global head of research and development, said in a statement. Regeneron's stock is up 1% in premarket trading on Monday, while it has gained 19% year-to-date. Shares of Sanofi are up 0.2% in premarket trading on Monday. Year-to-date, the company's stock is down 15%. The S&P 500 /zigman2/quotes/210599714/realtime SPX +0.16% is down 21% since the start of the year.

US : U.S.: Nasdaq
$ 641.76
-3.42 -0.53%
Volume: 434,877
Aug. 4, 2020 1:58p
P/E Ratio
Dividend Yield
Market Cap
$72.60 billion
Rev. per Employee
US : U.S.: Nasdaq
$ 51.79
-1.42 -2.67%
Volume: 951,315
Aug. 4, 2020 1:57p
P/E Ratio
Dividend Yield
Market Cap
$133.11 billion
Rev. per Employee
+5.19 +0.16%
Volume: 1.45B
Aug. 4, 2020 1:59p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.